O'Donnell Niall 4
4 · Mirum Pharmaceuticals, Inc. · Filed Nov 15, 2022
Insider Transaction Report
Form 4
O'Donnell Niall
Director
Transactions
- Sale
Common Stock
2022-11-11$19.99/sh−174,121$3,481,410→ 1,746,997 total(indirect: By RiverVest Venture Fund IV, L.P.) - Sale
Common Stock
2022-11-14$19.60/sh−32,109$629,423→ 1,714,888 total(indirect: By RiverVest Venture Fund IV, L.P.) - Sale
Common Stock
2022-11-15$19.69/sh−93,770$1,846,022→ 1,621,118 total(indirect: By RiverVest Venture Fund IV, L.P.)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.
- [F2]RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive.